UroGen Pharma

UroGen Pharma

Yahoo Finance • 8 days ago

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Last week, major U.S. indexes like the Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average have modestly gained by 0.52%, 0.42%, and 0.43%, respectively. Economic conditions remained complicated because of geopolitical tensi... Full story

Yahoo Finance • 22 days ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • last month

Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High

(RTTNews) - Today's top biotech gainers include Attovia Therapeutics, which surged following its Nasdaq debut; American Well, after reporting a narrower loss; Perrigo, which swung back to profit; and UroGen Pharma, following strong second-... Full story

Yahoo Finance • 2 months ago

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (NASDAQ:URGN) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value... Full story

Yahoo Finance • 3 months ago

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd.(NASDAQ:URGN), reported the sale of 5,222 ordinary shares for a total of approximately $143,000, as disclosed in a SEC Form 4 filing. Transaction summary Metric Value Shares sol... Full story

Yahoo Finance • 4 months ago

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.... Full story

Yahoo Finance • 4 months ago

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 4 months ago

Top global stories this week: Alibaba, Tencent among major names

Most stock indexes ended the week lower as investor sentiment remained cautious due to Iran conflict risks, inflation concerns, and weaker Wall Street trends after a hotter-than-expected U.S. inflation report. Tensions also rose after the... Full story

Yahoo Finance • 4 months ago

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.... Full story

Yahoo Finance • 4 months ago

UroGen outlines ZUSDURI path to “peak annual revenues exceeding $1 billion” while holding 2026 operating expense guidance at $240M-$250M

Earnings Call Insights: UroGen Pharma (URGN) Q1 2026 MANAGEMENT VIEW * “Given the critical importance of a successful ZUSDURI launch, the Board and I made the decision a few months ago that I would assume direct oversight of the commer... Full story

Yahoo Finance • 6 months ago

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securit... Full story

Yahoo Finance • 6 months ago

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics(NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter. What happened According to a Securities and Exchange Co... Full story

Yahoo Finance • 6 months ago

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names

On February 17, 2026, Superstring Capital Management disclosed a new position in Definium Therapeutics(NASDAQ:DFTX), acquiring 425,202 shares in the fourth quarter. What happened According to a SEC filing dated February 17, 2026, Superst... Full story

Yahoo Finance • 6 months ago

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish

On February 17, 2026, Superstring Capital Management reported selling 345,869 shares of Terns Pharmaceuticals(NASDAQ:TERN) in the fourth quarter, an estimated $7.99 million trade based on quarterly average pricing. What happened Accordin... Full story

Yahoo Finance • 6 months ago

UroGen (URGN) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Monday, March 2, 2026 at 10 a.m. ET Call participants President and Chief Executive Officer — Elizabeth A. Barrett Chief Medical Officer — Mark P. Schoenberg Chief Commercial Officer — David Lin Chie... Full story

Yahoo Finance • 7 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Uniti Group (UNIT [https://seekingalpha.com/symbol/UNIT]) * The Progressive Corporation... Full story

Yahoo Finance • 9 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the gra... Full story

Yahoo Finance • 10 months ago

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it... Full story

Yahoo Finance • 10 months ago

UroGen outlines $1B ZUSDURI peak revenue ambition as adoption set to accelerate with permanent J-code in 2026

Earnings Call Insights: UroGen Pharma Ltd. (URGN) Q3 2025 MANAGEMENT VIEW * CEO Elizabeth Barrett highlighted the progress of the ZUSDURI launch and noted, "The preliminary demand revenue for October is more than double the previous 3... Full story

Yahoo Finance • 10 months ago

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced robust... Full story